Novel phenoxyisobutyric acid compounds and methods for synthesis

Abstract

The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).

I claim: 
     
         1 . A compound of the formula: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . A pharmaceutical composition which comprises a compound as defined in  claim 1  and a pharmaceutically acceptable diluent. 
     
     
         3 . A method of inhibiting formation of gylcation end products or protein crosslinking resulting from glycation in a mammal in which it is desired to inhibit formation of glycation endproducts or protein crosslinking, wherein said method comprises administering an amount of a compound as defined in  claim 1  in an amount effective to inhibit the formation of glycation end products or protein crosslinking. 
     
     
         4 . A method of preventing or treating skin aging which comprises applying to the skin an effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt of said compound to said mammal. 
     
     
         5 . A method of treating rheumatoid arthritis, Alzheimer's disease, Wilson's disease, atherosclerosis, neurodegenerative diseases, neurotoxins and metabolic syndrome wherein said method comprises administering an effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt of said compound to said mammal 
     
     
         6 . A method of treating skin to increase the amount skin collagen which comprises applying to the skin an effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         7 . A method of preventing aging of the skin which comprises contacting skin with an effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt of said compound. 
     
     
         8 . A pharmaceutically acceptable salt of a compound of  claim 1  and a pharmaceutical carrier. 
     
     
         9 . A method of treating Type I diabetes which comprises administering to a Type I diabetic patient an effective amount of a compound of claim l or a pharmaceutically acceptable salt of said compound. 
     
     
         10 . A method of treating Type II diabetes which comprises administering to a Type II diabetic patient an effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt of said compound.